Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.60 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713288 | 0.92 | CRBN (0.61) | CRBNCSNK1A1IKZF2GSPT1DDB1 | |
| SCHEMBL22713284 | 0.92 | CRBN (0.61) | CRBNCSNK1A1IKZF2GSPT1DDB1 | |
| SCHEMBL29486601 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22713586 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL29486574 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22713168 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22713172 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22713174 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22713177 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL29486592 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269729-B | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2025-01-17 | — | — | CN | claimed |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-04-19 | — | — | US | claimed |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2022-07-07 | — | — | US | disclosed |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-20200377512-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-20200377512-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| WO-2020243379-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377512-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CPT1A, GOT2, IDH2 | CRBN 1290/4885CSNK1A1 798/4885IKZF2 4021/4885 |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CPT1A, GOT2, IDH2 | CRBN 1290/4885CSNK1A1 798/4885IKZF2 4021/4885 |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | CRBN 1290/4885CSNK1A1 798/4885IKZF2 4021/4885 |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | CRBN 1290/4885CSNK1A1 798/4885IKZF2 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.